journal
https://read.qxmd.com/read/34237273/a-contentious-fda-ruling-for-alzheimer-s-disease
#1
EDITORIAL
The Lancet Neurology
No abstract text is available yet for this article.
July 5, 2021: Lancet Neurology
https://read.qxmd.com/read/34237272/off-label-use-of-aducanumab-for-cerebral-amyloid-angiopathy
#2
LETTER
Steven M Greenberg, Charlotte Cordonnier, Julie A Schneider, Eric E Smith, Mark A van Buchem, Susanne J van Veluw, Marcel M Verbeek, Anand Viswanathan, David J Werring
No abstract text is available yet for this article.
July 5, 2021: Lancet Neurology
https://read.qxmd.com/read/34166643/world-brain-day-2021-a-call-to-stop-multiple-sclerosis
#3
LETTER
Tissa Wijeratne, Wolfgang Grisold, Peer Baneke, Anne Helme, Rachel King, William Carroll
No abstract text is available yet for this article.
June 21, 2021: Lancet Neurology
https://read.qxmd.com/read/34139157/2021-magnims-cmsc-naims-consensus-recommendations-on-the-use-of-mri-in-patients-with-multiple-sclerosis
#4
REVIEW
Mike P Wattjes, Olga Ciccarelli, Daniel S Reich, Brenda Banwell, Nicola de Stefano, Christian Enzinger, Franz Fazekas, Massimo Filippi, Jette Frederiksen, Claudio Gasperini, Yael Hacohen, Ludwig Kappos, David K B Li, Kshitij Mankad, Xavier Montalban, Scott D Newsome, Jiwon Oh, Jacqueline Palace, Maria A Rocca, Jaume Sastre-Garriga, Mar Tintoré, Anthony Traboulsee, Hugo Vrenken, Tarek Yousry, Frederik Barkhof, Àlex Rovira
The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016 Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and monitoring of multiple sclerosis made an important step towards appropriate use of MRI in routine clinical practice. Since their promulgation, there have been substantial relevant advances in knowledge, including the 2017 revisions of the McDonald diagnostic criteria, renewed safety concerns regarding intravenous gadolinium-based contrast agents, and the value of spinal cord MRI for diagnostic, prognostic, and monitoring purposes...
June 14, 2021: Lancet Neurology
https://read.qxmd.com/read/34118201/correction-to-lancet-neurol-2021-20-437-47
#5
(no author information available yet)
No abstract text is available yet for this article.
June 9, 2021: Lancet Neurology
https://read.qxmd.com/read/34015272/michael-moskowitz-solving-the-puzzle-of-migraine
#6
Udani Samarasekera
No abstract text is available yet for this article.
May 17, 2021: Lancet Neurology
https://read.qxmd.com/read/33933186/clinical-diagnosis-of-alzheimer-s-disease-recommendations-of-the-international-working-group
#7
REVIEW
Bruno Dubois, Nicolas Villain, Giovanni B Frisoni, Gil D Rabinovici, Marwan Sabbagh, Stefano Cappa, Alexandre Bejanin, Stéphanie Bombois, Stéphane Epelbaum, Marc Teichmann, Marie-Odile Habert, Agneta Nordberg, Kaj Blennow, Douglas Galasko, Yaakov Stern, Christopher C Rowe, Stephen Salloway, Lon S Schneider, Jeffrey L Cummings, Howard H Feldman
In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity...
April 29, 2021: Lancet Neurology
https://read.qxmd.com/read/34146515/mitochondrial-disease-in-adults-recent-advances-and-future-promise
#8
REVIEW
Yi Shiau Ng, Laurence A Bindoff, Gráinne S Gorman, Thomas Klopstock, Cornelia Kornblum, Michelangelo Mancuso, Robert McFarland, Carolyn M Sue, Anu Suomalainen, Robert W Taylor, David R Thorburn, Doug M Turnbull
Mitochondrial diseases are some of the most common inherited neurometabolic disorders, and major progress has been made in our understanding, diagnosis, and treatment of these conditions in the past 5 years. Development of national mitochondrial disease cohorts and international collaborations has changed our knowledge of the spectrum of clinical phenotypes and natural history of mitochondrial diseases. Advances in high-throughput sequencing technologies have altered the diagnostic algorithm for mitochondrial diseases by increasingly using a genetics-first approach, with more than 350 disease-causing genes identified to date...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146514/progress-towards-therapies-for-disease-modification-in-parkinson-s-disease
#9
REVIEW
Nirosen Vijiaratnam, Tanya Simuni, Oliver Bandmann, Huw R Morris, Thomas Foltynie
The development of interventions to slow or halt the progression of Parkinson's disease remains a priority for patients and researchers alike. To date, no agents have been shown to have unequivocal evidence of disease-modifying effects in Parkinson's disease. The absence of disease-modifying treatments might relate not only to inadequate approaches for the selection of therapeutic candidates but also to insufficient attention to detail in clinical trial design. Better understanding of Parkinson's disease pathogenesis associated with advances in laboratory models, the use of objective biomarkers of disease progression and target engagement, and a focus on agents known to be safe for human use, alongside the use of precision medicine approaches, should together greatly increase the likelihood for successful identification of disease-modifying treatments for Parkinson's disease...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146513/intracranial-pressure-monitoring-in-patients-with-acute-brain-injury-in-the-intensive-care-unit-synapse-icu-an-international-prospective-observational-cohort-study
#10
MULTICENTER STUDY
Chiara Robba, Francesca Graziano, Paola Rebora, Francesca Elli, Carlo Giussani, Mauro Oddo, Geert Meyfroidt, Raimund Helbok, Fabio S Taccone, Lara Prisco, Jean-Louis Vincent, Jose I Suarez, Nino Stocchetti, Giuseppe Citerio
BACKGROUND: The indications for intracranial pressure (ICP) monitoring in patients with acute brain injury and the effects of ICP on patients' outcomes are uncertain. The aims of this study were to describe current ICP monitoring practises for patients with acute brain injury at centres around the world and to assess variations in indications for ICP monitoring and interventions, and their association with long-term patient outcomes. METHODS: We did a prospective, observational cohort study at 146 intensive care units (ICUs) in 42 countries...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146512/safety-and-efficacy-of-pioglitazone-for-the-delay-of-cognitive-impairment-in-people-at-risk-of-alzheimer-s-disease-tommorrow-a-prognostic-biomarker-study-and-a-phase-3-randomised-double-blind-placebo-controlled-trial
#11
RANDOMIZED CONTROLLED TRIAL
Daniel K Burns, Robert C Alexander, Kathleen A Welsh-Bohmer, Meredith Culp, Carl Chiang, Janet O'Neil, Rebecca M Evans, Patrick Harrigan, Brenda L Plassman, James R Burke, Jingtao Wu, Michael W Lutz, Stephen Haneline, Adam J Schwarz, Lon S Schneider, Kristine Yaffe, Ann M Saunders, Emiliangelo Ratti
BACKGROUND: The identification of people at risk of cognitive impairment is essential for improving recruitment in secondary prevention trials of Alzheimer's disease. We aimed to test and qualify a biomarker risk assignment algorithm (BRAA) to identify participants at risk of developing mild cognitive impairment due to Alzheimer's disease within 5 years, and to evaluate the safety and efficacy of low-dose pioglitazone to delay onset of mild cognitive impairment in these at-risk participants...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146511/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised-myasthenia-gravis-adapt-a-multicentre-randomised-placebo-controlled-phase-3-trial
#12
RANDOMIZED CONTROLLED TRIAL
James F Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Temur Margania, Hiroyuki Murai, Malgorzata Bilinska, Roman Shakarishvili, Marek Smilowski, Antonio Guglietta, Peter Ulrichts, Tony Vangeneugden, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza
BACKGROUND: There is an unmet need for treatment options for generalised myasthenia gravis that are effective, targeted, well tolerated, and can be used in a broad population of patients. We aimed to assess the safety and efficacy of efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoantibody levels, in patients with generalised myasthenia gravis. METHODS: ADAPT was a randomised, double-blind, placebo-controlled, phase 3 trial done at 56 neuromuscular academic and community centres in 15 countries in North America, Europe, and Japan...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146510/safety-and-efficacy-of-occipital-nerve-stimulation-for-attack-prevention-in-medically-intractable-chronic-cluster-headache-icon-a-randomised-double-blind-multicentre-phase-3-electrical-dose-controlled-trial
#13
RANDOMIZED CONTROLLED TRIAL
Leopoldine A Wilbrink, Ilse F de Coo, Patty G G Doesborg, Wim M Mulleners, Onno P M Teernstra, Eveline C Bartels, Katja Burger, Frank Wille, Robert T M van Dongen, Erkan Kurt, Geert H Spincemaille, Joost Haan, Erik W van Zwet, Frank J P M Huygen, Michel D Ferrari
BACKGROUND: Occipital nerve stimulation (ONS) has shown promising results in small uncontrolled trials in patients with medically intractable chronic cluster headache (MICCH). We aimed to establish whether ONS could serve as an effective treatment for patients with MICCH. METHODS: The ONS in MICCH (ICON) study is an investigator-initiated, international, multicentre, randomised, double-blind, phase 3, electrical dose-controlled clinical trial. The study took place at four hospitals in the Netherlands, one hospital in Belgium, one in Germany, and one in Hungary...
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146509/who-is-in-control-of-artificial-intelligence-and-can-we-trust-them
#14
Jules Morgan
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146508/the-banality-of-head-injury-in-the-punisher
#15
Daniel M Donaldson, Henrik Holtmann, Julia Nitschke, Cihat Karadag, Richard Bostelmann, Benno Hartung, Lan Li, Athanasios K Petridis
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146507/poldi-wilbrink
#16
(no author information available yet)
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146506/form-and-function-in-the-brain
#17
Karl Deisseroth, Jane E Haley, Arpan R Mehta
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146505/giuseppe-citerio-s-neurocucina
#18
Adrian Burton
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146504/could-sars-cov-2-cause-tauopathy
#19
LETTER
James Pratt, Evan Lester, Roy Parker
No abstract text is available yet for this article.
July 2021: Lancet Neurology
https://read.qxmd.com/read/34146503/freezing-of-gait-and-levodopa
#20
LETTER
Moran Gilat, Nicholas D'Cruz, Pieter Ginis, Wim Vandenberghe, Alice Nieuwboer
No abstract text is available yet for this article.
July 2021: Lancet Neurology
journal
journal
20188
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"